0NES Stock Overview
Engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Oriola Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.07 |
| 52 Week High | €1.16 |
| 52 Week Low | €0.88 |
| Beta | 0.42 |
| 1 Month Change | 7.40% |
| 3 Month Change | 12.58% |
| 1 Year Change | 11.64% |
| 3 Year Change | -48.61% |
| 5 Year Change | -46.25% |
| Change since IPO | -61.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0NES | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | -4.2% | -0.7% | 0.3% |
| 1Y | 11.6% | -3.0% | 0.1% |
Return vs Industry: 0NES exceeded the UK Healthcare industry which returned -1.1% over the past year.
Return vs Market: 0NES exceeded the UK Market which returned -0.4% over the past year.
Price Volatility
| 0NES volatility | |
|---|---|
| 0NES Average Weekly Movement | 4.8% |
| Healthcare Industry Average Movement | 6.9% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: 0NES has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0NES's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1907 | 845 | Katarina Gabrielson | oriola.com |
Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company also distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products. In addition, it provides pharmaceutical logistics; special licensed medicine importing, dose dispensing, and research pharmacy services; and commercial data, clinical trial, regulatory affairs and quality, medical and scientific affairs, market access and tenders, real world evidence, sales support, medical translation, pharmacovigilance and medical information, and patient support services.
Oriola Oyj Fundamentals Summary
| 0NES fundamental statistics | |
|---|---|
| Market cap | €195.92m |
| Earnings (TTM) | -€23.20m |
| Revenue (TTM) | €1.75b |
0.1x
P/S Ratio-8.4x
P/E RatioIs 0NES overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0NES income statement (TTM) | |
|---|---|
| Revenue | €1.75b |
| Cost of Revenue | €1.59b |
| Gross Profit | €163.50m |
| Other Expenses | €186.70m |
| Earnings | -€23.20m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 18, 2025
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 9.33% |
| Net Profit Margin | -1.32% |
| Debt/Equity Ratio | 42.5% |
How did 0NES perform over the long term?
See historical performance and comparisonDividends
6.5%
Current Dividend Yield-55%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 05:47 |
| End of Day Share Price | 2025/05/12 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oriola Oyj is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Morten Larsen | ABG Sundal Collier |
| Iiris Theman | Carnegie Investment Bank AB |
| Panu Laitinmäki | Danske Bank |